Series B · Biotech · Zurich, Switzerland · Founded 2020 · 11–50 employees
GlycoEra AG is a biotechnology company developing novel biologics and best-in-class extracellular protein degraders for autoimmune diseases using its proprietary CustomGlycan platform and glycoengineering expertise. Founded in 2020 and spun out of LimmaTech, it has raised a CHF 45M Series A in 2022 and an oversubscribed $130M Series B in May 2025 led by Novo Holdings to advance its lead IgG4 degrader GE8820 into clinical trials and expand its pipeline. The company has appointed key executives like Ganesh Kaundinya as CEO and expanded its board with industry leaders.
No open roles listed right now.